Cost-effectiveness of prophylaxis with recombinant versus plasma-derived VWF in severe von Willebrand disease in the US

Christina Waldron; Satoko Ito; Daniel Wang; Cecily Allen; Giri Viswanathan; Robert D Bona; Adam Cuker; George Goshua

doi:10.1182/blood.2024024209

Cost-effectiveness of prophylaxis with recombinant versus plasma-derived VWF in severe von Willebrand disease in the US

Blood. 2024 Apr 18:blood.2024024209. doi: 10.1182/blood.2024024209. Online ahead of print.

Authors

Christina Waldron¹, Satoko Ito¹, Daniel Wang¹, Cecily Allen², Giri Viswanathan³, Robert D Bona⁴, Adam Cuker⁵, George Goshua¹

Affiliations

¹ Yale University School of Medicine, New Haven, Connecticut, United States.
² Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
³ Yale College, New Haven, Connecticut, United States.
⁴ Yale University, New Haven, Connecticut, United States.
⁵ University of Pennsylvania, Philadelphia, Pennsylvania, United States.

PMID: 38635764
DOI: 10.1182/blood.2024024209

Abstract

We evaluated the cost-effectiveness of prophylaxis with rVWF versus with pdVWF for patients with severe VWD. We found that rVWF is a cost-saving factor replacement compared to pdVWF across all willingness-to-pay thresholds in the United States.